Literature DB >> 2137785

Immunogenicity of yeast-derived hepatitis B vaccine from two different producers.

E Dahl-Hansen1, J C Siebke, S S Frøland, M Degré.   

Abstract

The immunogenicity and reactogenicity of two preparations of yeast-derived hepatitis B vaccines were compared in healthy adult populations. The two groups were vaccinated in parallel, but they were not matched for age and sex. All subjects seroconverted, and 9 months after the first vaccine dose, all had anti HBs titres of at least 10 IU/l. The anti-HBs titres were higher in the group of subjects given 20 micrograms vaccine antigen made by Smith Kline & RIT (GMT 2943 at 9 months) compared to those who received 10 micrograms of vaccine made by Merck, Sharp & Dohme (GMT 729 at 9 months). Adverse effects were recorded in 32.0 and 44.7% of the participants, but these were limited to minor local and general reactions. In the present study both preparations were safe and efficient.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2137785      PMCID: PMC2271739          DOI: 10.1017/s0950268800054625

Source DB:  PubMed          Journal:  Epidemiol Infect        ISSN: 0950-2688            Impact factor:   2.451


  14 in total

1.  Hepatitis B vaccines--to switch or not to switch.

Authors:  F B Hollinger
Journal:  JAMA       Date:  1987-05-15       Impact factor: 56.272

2.  The assessment of immunity against hepatitis B after vaccination.

Authors:  W Frisch-Niggemeyer; F Ambrosch; H Hofmann
Journal:  J Biol Stand       Date:  1986-07

3.  Clinical evaluation of a recombinant hepatitis B vaccine.

Authors:  W Jilg; B Lorbeer; M Schmidt; B Wilske; G Zoulek; F Deinhardt
Journal:  Lancet       Date:  1984-11-24       Impact factor: 79.321

4.  Immunogenicity of recombinant yeast hepatitis B vaccine.

Authors:  M Davidson; S Krugman
Journal:  Lancet       Date:  1985-01-12       Impact factor: 79.321

5.  Expression of hepatitis B surface antigen in yeast.

Authors:  N Harford; T Cabezon; M Crabeel; E Simoen; A Rutgers; M De Wilde
Journal:  Dev Biol Stand       Date:  1983

6.  Hepatitis B. Taiwan plans mass vaccination.

Authors:  R Walgate
Journal:  Nature       Date:  1984 Nov 15-21       Impact factor: 49.962

7.  Synthesis and assembly of hepatitis B virus surface antigen particles in yeast.

Authors:  P Valenzuela; A Medina; W J Rutter; G Ammerer; B D Hall
Journal:  Nature       Date:  1982-07-22       Impact factor: 49.962

8.  A controlled clinical trial of the efficacy of the hepatitis B vaccine (Heptavax B): a final report.

Authors:  W Szmuness; C E Stevens; E A Zang; E J Harley; A Kellner
Journal:  Hepatology       Date:  1981 Sep-Oct       Impact factor: 17.425

9.  Comparison of the immunogenicity of reduced doses of two recombinant DNA hepatitis B vaccines in New Zealand children.

Authors:  A Milne; T A Brawner; P C Dumbill; I Kawachi; N E Pearce
Journal:  J Med Virol       Date:  1989-03       Impact factor: 2.327

10.  Long-term immunogenicity and efficacy of hepatitis B vaccine in homosexual men.

Authors:  S C Hadler; D P Francis; J E Maynard; S E Thompson; F N Judson; D F Echenberg; D G Ostrow; P M O'Malley; K A Penley; N L Altman
Journal:  N Engl J Med       Date:  1986-07-24       Impact factor: 91.245

View more
  5 in total

Review 1.  Adverse events after hepatitis B vaccination.

Authors:  P Duclos
Journal:  CMAJ       Date:  1992-10-01       Impact factor: 8.262

2.  Reducing alcohol consumption. Comparing three brief methods in family practice.

Authors:  M C McIntosh; G Leigh; N J Baldwin; J Marmulak
Journal:  Can Fam Physician       Date:  1997-11       Impact factor: 3.275

3.  Factors influencing immunologic response to hepatitis B vaccine in adults.

Authors:  Shigui Yang; Guo Tian; Yuanxia Cui; Cheng Ding; Min Deng; Chengbo Yu; Kaijin Xu; Jingjing Ren; Jun Yao; Yiping Li; Qing Cao; Ping Chen; Tiansheng Xie; Chencheng Wang; Bing Wang; Chen Mao; Bing Ruan; Tian'an Jiang; Lanjuan Li
Journal:  Sci Rep       Date:  2016-06-21       Impact factor: 4.379

Review 4.  From empiricism to rational design: a personal perspective of the evolution of vaccine development.

Authors:  Ennio De Gregorio; Rino Rappuoli
Journal:  Nat Rev Immunol       Date:  2014-06-13       Impact factor: 53.106

Review 5.  Structural and Computational Biology in the Design of Immunogenic Vaccine Antigens.

Authors:  Lassi Liljeroos; Enrico Malito; Ilaria Ferlenghi; Matthew James Bottomley
Journal:  J Immunol Res       Date:  2015-10-07       Impact factor: 4.818

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.